



6-15-2018

# To Randomize Or Not to Randomize? That is the Question

Robert Boruch

*University of Pennsylvania*, [robertb@gse.upenn.edu](mailto:robertb@gse.upenn.edu)

Follow this and additional works at: [https://repository.upenn.edu/gse\\_pubs](https://repository.upenn.edu/gse_pubs)

 Part of the [Education Commons](#)

---

## Recommended Citation

Boruch, R. (2018). To Randomize Or Not to Randomize? That is the Question. Retrieved from [https://repository.upenn.edu/gse\\_pubs/445](https://repository.upenn.edu/gse_pubs/445)

This paper is posted at ScholarlyCommons. [https://repository.upenn.edu/gse\\_pubs/445](https://repository.upenn.edu/gse_pubs/445)  
For more information, please contact [repository@pobox.upenn.edu](mailto:repository@pobox.upenn.edu).

---

# To Randomize Or Not to Randomize? That is the Question

## **Abstract**

Women Affirming Motherhood (WAM) recently received substantial support from the Empire Foundation for WAM's work in assisting pregnant young women. As part of the grant, Empire required WAM to elicit bids for an independent evaluation of WAM's performance. In what follows, the focus is on evaluating WAM's effects. In particular, the concern is whether and how a randomized controlled trial (RCT) might be deployed so as to produce a fair estimate WAM's effects.

The approach to addressing the concern is interrogatory, as the title suggests. The topic's handling here is more Socratic than it is Shakespearian, however.

## **Disciplines**

Education

Title: To Randomize Or Not to Randomize? That is the Question.

Author: Robert Boruch

Date: September 2 615PM

Word Count: 3600

Prepared for: Alkin & Christie. NDE Journal Volume, and AEA session Nov 6-11 2017

Status: Draft

University of Pennsylvania  
Graduate School of Education  
3700 Walnut Street  
Philadelphia, PA 19104  
[robertb@gse.upenn.edu](mailto:robertb@gse.upenn.edu)

To Randomize or Not to Randomize?

That is the Question.

Robert Boruch

University of Pennsylvania

June 15, 2018

### **Introduction**

Women Affirming Motherhood (WAM) recently received substantial support from the Empire Foundation for WAM's work in assisting pregnant young women. As part of the grant, Empire required WAM to elicit bids for an independent evaluation of WAM's performance. In what follows, the focus is on evaluating WAM's effects. In particular, the concern is whether and how a randomized controlled trial (RCT) might be deployed so as to produce a fair estimate WAM's effects.

The approach to addressing the concern is interrogatory, as the title suggests. The topic's handling here is more Socratic than it is Shakespearian, however.

### **Assumptions about WAM and Interest in Its Effects**

Program managers, foundation people, and a prospective trialist must depend on assumptions about the state of play. This article depends on Alkin and Christie' (2017) characterization of the program (2017). In particular, WAM's targets are declared to be expectant mothers in low income areas. WAM's leadership includes able people who developed what they believe to be a promising program. With foundation funding, the assumption is that

the WAM staff will continue to service the mothers. If this information is not dependable, the trialist may withdraw from engagement.

The prospective trialist may assume, or must assume, that the potential users of evidence about WAM's effect are serious in this interest. Identifying the potential users is important to support this assumption. For instance, they may include WAM's leadership and staff, the Empire Foundation, and other stakeholders including WAM's target population. For the trial's design, an advisory panel that includes such people is usually helpful to the design process. More about this anon.

If there is no real prospect of fair evidence being used by any of these stakeholders, or if there will be no serious input from stakeholders in the trial's design, there's not much point to a trialist going further.

### **Interrogatory Approach to Deciding about RCTs, And Their Design.**

In evaluation studies generally, and in deciding about whether to engage in RCTs in particular, three questions are fundamental.

Q1. What's the nature, severity of the problem and how do we know?

Q2. Has the program that's designed to address the problem been deployed, and how do we know?

Q3. What's the program's effect and how do we know?

These questions, put in other vernacular, underlie evaluation policies of some foundations, multi-national organizations, and federal agencies in the U.S. and in textbooks on evaluation. See for instance Boruch, Chao, Lee (2016) and especially the references therein.

Addressing the last question, about effect, depends heavily on evidential answers to the first two questions. Absent good evidence on these two, designing good RCTs, or any impact study is likely to be unsatisfactory at best. It may be and futile at worst. Each question is considered in the WAM context in what follows.

### **Q1. What's the Nature and Magnitude of the Problem and How Do We Know?**

Alkin and Christies (2017) report that WAM's take-up rate at the end of the first-year was "a little more than 100 expectant mothers were served...with demand for service increasing regularly..." (p2). Page 3 of the report further avers that "...the number of young women seeking WAM's services was steadily growing..." in Year 2. This is promising for funders of course.

For a trialist however, the information is vague. Demand is said to be "Increasing regularly....and steadily growing" But the trialist must ask: by how much exactly? "Steadily Ten percent? Two percent? What? Determining how much is important partly because designing a good RCT depends on the trialist's understanding of the number of young women in WAM's pipeline. Pipeline studies are required in advance of many RCTs in medical, criminological, and educational sectors. In reporting on final results of a trial, the CONSORT Standards, for instance, require such information to assure transparency of RCTs results. See <http://www.consort-statement.org>.

More to the point of designing a RCT so as to estimate WAM's effects, small samples, such as 100-200, often require special attention from the trialist. The mobility of the young women is important. If they disappear fast from the WAM pipeline, WAM's effect will be difficult to detect or understand. A good trialist might then suggest that WAM's evaluation then be considered an exploratory effort, rather than a confirmatory or summative effort.

In particular, the trialist may suggest that (a) the small sample study be considered as exploratory and (b) the probability of outcomes be the focus rather than formal tests of statistical hypotheses. Randomization tests for instance, give a probability of a difference in outcomes, as opposed to inviting, or being seduced into, formal decisions about decisions based on a  $p=.05$  or some other artificial threshold. The fourth edition of the Edgington and Orghena (2007) book is a dependable resource on this account.

A rather more interesting aspect of the WAM scenario concerns WAM's "client base," referenced on page 3. No information is provided about the base, apart from telling us that the young ladies are pregnant, at high risk, and living in a poor area of a mid-western city. Who refers the women to WAM? More important, who are these young people? Are they school age? In prisons? On welfare? Obese? On drugs? Are they transient? Or all? Understanding what the client base here is important in understanding the nature and magnitude of the problem, and hence in designing a RCT. Ditto for the broader context.

Absent dependable information on the young ladies in the WAM pipeline, it's difficult, or impossible, to design a good RCT. No decent statistical power analysis is possible, for instance. No sensible interpretation of the RCT's results, including generalizability, is possible absent dependable information on the WAM client base and referral system.

If there is good initial evidence on these matters, the trialist may then proceed further. Otherwise, he or she may pull the plug, for good reason.

## **Q2. Is the Program Deployed and How Do We Know?**

Over the past 40 years, big foundations have given big dollars to programs that have not been deployed. Nowadays, the best foundations require evidence about this. They ask how the money was spent. Bless Empire on this account, if indeed the foundation asks WAM about the dollars.

Evaluators who specialize in program implementation or formative assessments are typically more informative about program operations and practice than a specialist in RCTs can be. Specialists in formative evaluation, for instance, can assist in understanding WAM's deployment, and how WAM's services cut across agencies. Any given service component may demand attention to indicators of service delivery and receipt. Undergirding the deployment is a theory of change, i.e., a set of ideas about what should happen in WAM's service delivery and about what should happen to young women as a consequence of its delivery.

In designing a randomized trial, the prospective trialist would be foolish to ignore WAM's theory of change, and the evidence that might be offered by implementation specialists about WAM's deployment. Absent such evidence, or the promise of it, the trialist may desist from further work. The trialist may then proceed if there is a promise of evidence on WAM's deployment in addition to evidence on WAM's client base.

## **Q3. What is WAM's effect? How Do We Know?**

In the case at hand, designing a randomized controlled trial depends on evidential answers to Questions 1, on WAMs' pipeline and client base, and Question 2, on WAM's deployment. Let us assume that the questions have been addressed, or will be addressed as part of a trial.

This get to the hard work by the trialist: reviewing the relevant literature, identifying the main outcome variables, structuring the random allocation and explanations of it, and tagging a trial so as to benefit from inevitable mistakes.

### **Reviewing the Relevant Literature**

Industrious trialists will inquire of colleagues who have done related work so as to learn from them. For the WAM case, a trialist will try to learn from the published literature who has measured what in randomized field experiments that have direct attention to young pregnant women in high poverty areas, how, when, and why the trial was done, and what the outcomes were.

In the health care sector, for instance, the Cochrane Collaboration regularly produces reviews of evidence on related programs. The Cochrane Library covers evidence on effectiveness of interventions designed to avert or handle domestic violence against pregnant women, the antenatal issues that affect women in low income areas, and the handling of pre-natal and post-natal health and behavior issues among the women. See <http://cochrane collaboration.org>.

### **Outcome Measures**

Deciding which outcome variables should be measured is no easy matter in a multicomponent program like WAM. WAM's stakeholders and Foundation people are important in this, as is the theory of change.

The burden falls partly to the trialist to encourage identification of pertinent outcomes, and often to identify dependable ways to measure them. The programmatic or policy decision about what outcome to measure is usually not in the trialist's purview.

Snares in any such negotiation on this are common. The challenges for the trailist include the WAM's opining that a dozen outcomes are important. The health of the young woman and health of the baby are, to be sure, relevant. But so too are outcomes such as the women's knowledge and perhaps also her beliefs, attitudes, and observable links to the social networks that WAM facilitates.

Typically, all potential outcomes are not equally important to everyone. The trialist, must nonetheless seek agreement on which one or two or three outcomes have the highest priority and why. Setting priorities is basic because: (a) measuring all plausible outcomes well is likely to be infeasible, (b) measuring lots of plausible outcomes guarantees that some effects will be positive, some negative, and many will be negligible, which inevitably leads to squabbles about the implications of results, and (c) identifying a couple of primary outcomes does not mean that others be ignored. The result of negotiation usually entails classifying outcome into the primary ones and the ones of secondary import.

Absent a negotiated agreement that a couple of outcomes are high priority and can be measured dependably, and absent agreement that there are secondary outcomes that are important and measureable, a prospective trialist may excuse himself or herself without disgrace.

## **Random Allocation and Fairness**

Designing a RCT in this context requires some agreement among stakeholders about random allocation of pregnant young women, to WAM or to a control condition (which might be an existing community program). The random allocation will yield defensible evidence that the estimated effect is transparent and fair.

For example, if the demand for WAM's services far exceed WAM's capacity to supply services, then random allocation of young pregnant women to the WAM program may be acceptable to stakeholders. The negotiation on this may involve ethical, managerial, and political values. It depends of course on the realities of the pipeline.

When demand exceeds supply, and when lottery allocation is acceptable to stakeholders, the technical issues in design are easy. For instance, trialists have easy access to software for substantial power analysis, assuring that a WAM effect can be detected, e.g. Dong and Maynard (2013). Trialists have easy access to technology that incorporates factors such a types of pregnant women (single mothers, drug users, diabetics) into the experiment's design.

Statistical power analysis is merely technical. It is not enough. In designing the RCT, good trialists will review work on earlier trials on programs that seem relevant. Systematic reviews, of the sort published by the Cochrane Collaboration in health and the Campbell Collaboration in social sectors, are relevant. These are important to anticipate WAM's effect size, to understand what outcomes are important.

WAM's aims, the challenge of designing a good trial, and systematic reviews lead to a basic question for the trialist. What are the outcome variables? And who says so? And how might these outcomes be measured or observed dependably?

## **Ethics and Random Assignment**

WAM's description does not tell us that the program is mandatory, ordered by a family court for instance. Assume, as is usually the case, that the women's participation in the program is voluntary. In such cases, the idea of informed consent is important. Consent is crucial. But there are other ethics issues in this scenario.

Is the program important enough to test in a trial? If it not, then the results of a trial may be trivial at best and may waste people's time. Assume that WAM is important enough to justify a trial. Ethics questions remain.

If WAM's important ingredients are known to be effective, based on earlier dependable evidence, deploying a randomized trial may not be warranted. For instance, no one does Salk vaccine trials nowadays to test the vaccine's effectiveness because effects have been well established. One might however ethically test WAM's variation under the assumption that it is potentially better than others, just as testing different doses of vaccines can be ethical.

Would methods other than a randomized trial yield dependable evidence about its effects? If so, randomization may not be necessary and even be unethical. For instance, times series data on women in WAM's catchment area might be sufficient, when the interruption of the series, if the deployment of the program is sharp, and the time series data are adequate. In the case at hand, neither "if's" are likely to be met.

One might explore propensity score approaches, which are more sophisticated than older covariance analyses. These require identifying the right matching variables (covariates), measuring them in the right way, and putting them into the right functional form/model for reasonably defensible statistical estimates of effect. Identifying and discussing alternatives to random assignment as a device to produce fair comparisons are typically debatable matters.

Assume for the sake of argument, that the alternatives are not feasible, will not yield persuasive evidence, or will yield evidence that is far less transparent than a randomized trial results would be. The trialist may then proceed.

### **Explaining Random Allocation to Young Pregnant Women**

How does one explain to pregnant young women the fact that they will be randomly allocated to a special program? Experience from other sectors suggests that explanations have to be tailored to the people involved. To cut to the rhetorical chase, the word “experiment” in some contexts is unacceptable. The phrase “randomized controlled trial” is meaningless in others. The word “lottery” may be tolerable, and familiar, in common parlance. The idea of a lottery is fair in many cultures.

Learning how to explain well can depend on focus groups of potential WAM participants in anticipation of the RCT, and on the judgments of stakeholders of course. See for instance Rockefeller Foundation’s video tape documentary on the Minority Female Single Parent Program. The taping grew out of initially flawed efforts to explain in the trial and shows how explanation may differ with culture.

### **Executing an RCT under Uncertain or Unstable Conditions**

Absent pre-RCT efforts and evidence, the trialist will be a troubled soul. Less troubled than Hamlet, but troubled nonetheless. In uncertain conditions, one option is obvious. The trialist might run the trial in two stages. The first stage, a “run-in trial” in engineering parlance is deployed so everyone makes all the mistakes one can make. The trialist and everyone else can then learn how to deploy the second stage and do a better trial.

In olden days for instance, cops, nurses, and other service providers subverted the random allocation at times, e.g. by simply ignoring the assignment and treating the client as they pleased. Audits and mechanisms can be built to suit the particular setting so as to reduce or eliminate the problem. Similarly, information that permits tracking of women over time can be built based on experience so as to reduce attrition, missing data, and so on. Doing RCTs in stages is a no brainer for trialists in the social sciences, health, engineering, physical sciences.

### **Small Sample Issues**

WAM's pipeline is modest, involving 100 young women in each cohort. For the trialist, this invites two themes. One concerns rhetoric and policy. The second directs attention to technical approaches to handling the matter. They are interrelated.

Small samples of program participants invites the trialist, and WAM's stakeholders, to denominate the study as exploratory, or as a pilot test. This nomenclature reflects a reality. Its use is important in reducing temptation to over advertise potential results. More important, it lays the groundwork for scaling up or for scaled up trials if indeed the pilot yields promising results.

Even in small samples, random assignment guarantees that there will be no *systematic* bias in comparing WAM's outcomes to a control condition or to other programs. This is fundamental. Nonetheless, chance outcomes should be taken into account. This is despite the fact artificial thresholds such as p values and statistical power recede in their importance for small samples in pilot efforts, and that the magnitude of a discernable difference is important.

Instead of formal tests of hypotheses and the conventional power standards, the trialist may employ simpler approaches invented by Fisher, and elaborated and accompanied by software by Edgington and Orghena (2007) among others. Consider the following illustration.

Suppose that the outcome variable indicates each woman's well being on a score with range 1-5. Further suppose that the sample is really small, with 5 young ladies being randomly assigned to WAM and 5 randomly assigned to a control condition. Such a sample is far too small for conventional power analyses or tests of hypotheses unless the expected effect size is huge, i.e. the trialist and stakeholders are absurdly optimistic.

In simple randomization tests, one ignores the actual assignments and identifies all possible assignments of each woman to a group. In a scenario involving 10 women assigned to two groups, there are 252 such assignments. One then computes the 252 mean differences in the scores of the two groups so composed. At one extreme, for instance, all women in one group may have scores of 5 and all women in the other condition have scores of 1, leading to a simple difference in average scores of 4. At another extreme, all women in each group may have the same scores, leading to an average difference in outcomes of zero. Beyond these extremes, there is lots of variation.

In this hypothetical scenario, 15% of all the average differences between groups may be "big" by chance, i.e. an average difference of 1 or more. If the actual observed difference in the trial is 1, then one may conclude that the magnitude is big and further that the probability level is tolerably small if there is no real WAM effect. It is not statistically significant under a 5% threshold value, but the result is promising.

## **Concluding Remarks**

As readers might surmise, developing fair and transparent estimates of the effects of new programs is hard work. This is the case for WAM as well as others. The steps need to do the job right are numerous. To some, they are tedious and not fast enough.

In other scenarios, experiments can indeed be brisker. The Silicon Valley slogan, “Fail often and fast,” embodies a different perspective on trials for instance. The context of differs. Computer chips are irrelevant to ethical issues. Web based commercial experiments on influencing site user preferences, however, usually involve fewer steps and less complex “programs” than something like WAM.

The series of questions enunciated above can be reconfigured as checklist items, of course. Taking a checklist approach helps to assure (a) procedural simplicity, (b) action topics are covered, (c) the generation of a dependable scientific log on the experiments, and (d) ingredients for interim and final reporting on WAM’s effects.

Questions other than the three that are posed here can be laid out. For instance, can QWAM be replicated and might the results of this particular WAM trial be replicated again in the same and other contexts? Further, how might the results of repeated trials on WAM like programs be recorded and submitted to systematic review. Though organizations such as Campbell Collaboration, the Cochrane Collaboration, and others do a good job, they cannot do the job well if results of trials are not reported.

Making incremental progress to assist young pregnant women in low income neighborhoods in their learning how to make progress on their own is important. The evidence on progress is a product of randomized trials. Absent dependable evidence, the young women and we will make little or no progress.

## References

Alkin, Marvin and Christie, Tina (2017) *Women Affirming Motherhood. Scenario*. Los Angeles, CA: UCLA. Word Doc. *Email from Alkin to Contributors on NDE Evaluation Theorists' Models Part II*, February 9, 2017.

Boruch, Robert, Chao, Jessica, and Lee, Selene (2016) Program Evaluation Policy, Practice and Use of Results. *Comparative Education Research Quarterly*, 24 (4), 71-90. DOI 10.6151/CERQ.2016.2404.03.

CONSORT (2017). *Transparent Reporting of Trials*. <http://consort.statmemrt.org>.

Dong, N., & Maynard, R. A. (2013). PowerUp!: A tool for calculating minimum detectable effect sizes and minimum required sample sizes for experimental and quasi-experimental design studies. [Software]. <http://www.causalevaluation.org/>

.

Edgington, Eugene and Onghena, Patrick (2007) *Randomization Tests*. Boca Raton Florida: Chapman and Hall/CRC/Taylor and Francis.